moomoo ID:NaN
Log Out
Log in to access Online Inquiry

StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

Financial News Live ·  {{timeTz}}

StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a report published on Monday. The brokerage issued a sell rating on the biotechnology company's stock.

Bellerophon Therapeutics Price Performance

BLPH stock opened at $1.03 on Monday. The company has a 50 day moving average price of $1.32 and a 200 day moving average price of $1.41. Bellerophon Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $4.49. The stock has a market capitalization of $9.83 million, a PE ratio of -0.53 and a beta of -0.07.

Get Bellerophon Therapeutics alerts:

Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) last posted its quarterly earnings data on Monday, August 15th. The biotechnology company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.18. As a group, equities analysts expect that Bellerophon Therapeutics will post -2.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bellerophon Therapeutics stock. Sepio Capital LP bought a new stake in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 23,800 shares of the biotechnology company's stock, valued at approximately $29,000. Sepio Capital LP owned about 0.25% of Bellerophon Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 11.92% of the company's stock.

About Bellerophon Therapeutics

(Get Rating)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Featured Articles

  • Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
  • Humana Proves Vertically Integrated Healthcare Works
  • What Cintas Can Teach Investors About This Bear Market?
  • 2 Casino Stocks Worth Taking a Look At
  • This Small-Cap Healthcare Name Is Outperforming Its Index
  • Blackberry Stock Declines As Results Come In Lukewarm Once Again

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.